Company Overview
Snapshot
Founded in June 2004 by Shaike Schatzberger, UC-CARE operates with 11–50 employees. The company has raised $1.56M across two funding rounds from two investors. In March 2019, the company secured funding from Florida Funders to support its expansion.
Business overview
UC-CARE develops a patented diagnostic and treatment system designed to improve procedures for prostate diseases. Its core technology aims to solve the problem of blind biopsies and provide an improved system for focal treatment. Key products include Navigo, a device for high-resolution 3D imaging and biopsy sample recording; Navigo Viewer, a patient CD for procedure summaries; SmartBx, a biopsy core preservation and management system; and Navigo Fusion Studio, a software solution for fusion planning. The company serves the health tech and life sciences sectors, focusing on medical devices, diagnostics, and medical treatments globally.
Strategic signal
In September 2016, UC-CARE announced the Navigo and SmartBx systems, highlighting a new vision for prostate MRI fusion biopsy. This development signals the company's commitment to advancing diagnostic and treatment technologies in urology, offering a more precise and efficient approach to prostate cancer management for healthcare providers and patients.
Log in to access full profile ›Company Intelligence Q&A
- When was UC-CARE founded and by whom?
- UC-CARE was founded in June 2004 by Shaike Schatzberger.
- What is the Navigo system?
- Navigo is a device developed by UC-CARE that enables physicians to image, plan, place, and record prostate biopsy samples in high-resolution 3D, allowing for more confident sampling and future reference.
- What is SmartBx?
- SmartBx is a biopsy core preservation and management system from UC-CARE designed to integrate seamlessly into the TRUS biopsy procedure, contributing to improved cancer detection and management, particularly for active surveillance processes.